计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 2 篇同行评审文献引用。
概述
Tranilast is an antiallergic drμg by inhibiting lipid mediator and cytokine release from inflammatory cells, used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.An inhibitor of angiogenesis and the release of histamine and prostaglandins.
Information
Tranilast (SB 252218, MK-341, Rizaben, MK 341, Tranpro) is anantiallergicdrug by inhibiting lipid mediator and cytokine release from inflammatory cells, used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
In vitro
Tranilast is an anti-allergic drug inhibiting the release of substances such as histamine and prostaglandins from mast cells, which suppresses collagen synthesis of fibroblasts derived from keloid tissues. Tranilast (3-300 mM) suppresses the collagen synthesis of fibroblasts from keloid and hypertrophic scar tissue but not healthy skin fibroblasts. Tranilast (30-300 mM) inhibits the release of transforming growth factor (TGF)-beta 1 from keloid fibroblasts, which enhances the collagen synthesis of keloid fibroblasts. Tranilast improves keloids and hypertrophic scars which originate from the abnormal proliferation and excessive collagen accumulation of fibroblasts. Tranilast inhibits the release of TGF-beta 1, IL-1 beta and PGE2 from the human monocytes-macrophages. Tranilast inhibits the proliferation stimulated with fetal bovine serum (FBS), TGF-beta 1 and platelet-derived growth factor-BB (PDGF-BB) as well as PDGF-BB-induced migration. Tranilast exhibits inhibitory effects on spontaneous collagen synthesis and TGF-beta 1-induced collagen and glycosaminoglycan synthesis.
In vivo
Tranilast results in a 58% reduction in TGF-beta1-induced 3[H]-hydroxyproline incorporation in the diabetic heart of rats. Tranilast attenuates cardiac fibrosis by 37% in association with reduction in phospho-Smad2 in the diabetic heart of rats. Tranilast treatment completely prevents the increase in chymaselike activity, reduces the chymase mRNA levels by 43%, and decreases the carotid intima/media ratio by 63% in the carotid artery of dogs.
Cell Data
cell lines：MOLM-13 and RS4;11 cells
Concentrations：
Incubation Time：
Powder Purity:≥99%
规格
英文别名
MK-341, Rizaben, MK 341, Tranpro | (E)-2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic acid
规格或纯度
10mM in DMSO
英文名称
Tranilast (SB 252218)
生化机理
曲尼司特（SB 252218、MK-341、Rizaben、MK 341、Tranpro）是一种抗过敏药物，通过抑制炎症细胞释放脂质介质和细胞因子，用于治疗哮喘、过敏性鼻炎和特应性皮炎等过敏性疾病。
储存条件
-80℃储存
运输条件
特低温运输
名称和识别符
EC号
621-256-5
分子类型
小分子
Isomeric SMILES
COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
关联CAS
分子量
327.33
Reaxy-Rn
3987703
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3987703&ln=
技术文档
高级数据
关联靶点（人）
ABCC4
Tchem
多药耐药相关蛋白 4(Multidrug resistance-associated protein 4)
(0 活性数据)
化学和物理性质
熔点
166.2-168.2 °C
安全和危险性（GHS）
象形图
信号词
Warning
危险声明
H302: 吞食有害
预防措施声明
P501: 将内容物/容器处理到。。。
P264: 处理后要彻底洗手。
P270: 使用本产品时，请勿进食、饮水或吸烟。
P330: 漱口
P301+P317: 如果被吞咽：请寻求医疗帮助。
WGK Germany
3
RTECS
DG8731000
Merck Index
9570
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
此产品的引用文献
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）